arrow
D

Dominik Hlauschek

Medical University of Graz
H指数:8
被引数:476

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The Xpert Breast Cancer Insight Test Predicts Distant Recurrence and Overall Survival in ER-Positive, HER2-Negative Early Breast Cancer

Xpert乳腺癌洞察测试可预测ER阳性、HER2阴性早期乳腺癌的远处复发和总生存期

2026-07-010
OAAI
Body Mass Index in Postmenopausal Women with Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer: An Exploratory Analysis of the LORELEI trial.

雌激素受体阳性、HER2阴性早期乳腺癌绝经后女性中的体重指数:LORELEI试验的探索性分析

2026-06-120
PRE
Integrating baseline ctDNA-derived tumor metrics enhances risk stratification in HR-positive/HER2-negative advanced breast cancer: a real-world multicenter cohort study from Austria

整合基线ctDNA衍生的肿瘤指标可增强HR阳性/HER2阴性晚期乳腺癌的风险分层:一项来自奥地利的真实世界多中心队列研究

2026-03-310
OAAI
Correction: Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer

更正:在PALLAS全球随机临床试验中,palbociclib对早期乳腺癌患者正在进行辅助内分泌治疗的治疗依从性的影响

2026-02-180
PRE
ESR1, PGR, ERBB2, and MKi67 mRNA expression in diagnostic core biopsies from breast cancer patients of the ABCSG Trial 34

ABCSG试验34中乳腺癌患者诊断性核心活检样本中的ESR1、PGR、ERBB2和MKi67 mRNA表达

2025-10-300
OAAI
A core outcome set for locoregional treatment reporting in neoadjuvant systemic breast cancer treatment trials

新辅助系统性乳腺癌治疗试验中局部区域治疗报告的核心结局指标集

2025-10-280
OA
Palbociclib with adjuvant endocrine therapy in early breast cancer: five-year follow up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13)

帕博西利联合辅助内分泌疗法在早期乳腺癌中的应用:全球多中心、开放标签、随机III期PALLAS试验(ABCSG-42/AFT-05/PrE0109/BIG-14-13)五年随访分析

2025-10-170
OAAI
Clinical impact of single-gene vs. panel sequencing in advanced HR + /HER2− breast cancer: insights and implications

单基因测序与基因panel测序在晚期HR+/HER2-乳腺癌中的临床影响:见解与启示

2025-08-070
OAAI
Validation of the CTS5 in four prospective, multicenter, randomized ABCSG trials
BREAST
IF7.9
2025-04-010
OAAI
Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer
2025-03-010
PRE
Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13])
2025-01-230
OAAI
HER2 and HER3 expression during neoadjuvant treatment of HER2-negative early breast cancer: potential for biomarker-driven sequencing of T-DXd and HER3-DXd

HER2和HER3在HER2阴性早期乳腺癌新辅助治疗期间的表达:T-DXd和HER3-DXd生物标志物驱动的序贯治疗的潜力

2025-01-060
PRE
Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42/AFT-05/BIG-14-13/PrE0109)
2024-10-070
OAAI
Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting? (Jan, 10.1007/s10549-023-07186-6, 2024)
2024-05-050
OAAI
The impact of drug-drug interactions between palbociclib and proton pump inhibitors on clinical outcomes of patients with hormone receptor positive, HER2-negative, early breast cancer: an exploratory analysis of the PALLAS study
2024-05-020
PRE
Zoledronic acid to prevent rebound fractures after stopping adjuvant denosumab: a randomized controlled sub-study of the ABCSG-18 trial
2024-05-020
PRE
Pathological response according to early metabolic remission in an interim FDG-PET scan and to tumor infiltrating lymphocytes - A secondary analysis of the phase II trial ABCSG 52/ATHENE investigating atezolizumab in early HER2+BC
2024-05-020
PRE